OncoSec Medical Inc.
Electroporation drug delivery for advanced skin cancer
This article was originally published in Start Up
Executive Summary
OncoSec Medical Inc. has developed electroporation-based technology for deadly Stage III and IV metastatic melanoma, and two rare but aggressive orphan skin cancer indications. Its ImmunoPulse platform delivers DNA IL-12 into electroporated cells, triggering each cell to produce and secrete the IL-12 protein, which in turn identifies and eliminates cancerous cells as part of a natural immune response.